CD33 and acute myeloid leukemia: In the single terminated CD-33 CAR T-cell clinical trial at M.D. Anderson Cancer Center, United States, three adult r/r AML patients received anti-CD33 CAR T-cells at a dose level (0.3 x 10^6 cells/kg) (22).